A citation-based method for searching scientific literature

Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
Times Cited: 259



Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
Times Cited: 4428




List of shared articles



Times cited


A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro. Cardiovasc Diabetol 2021
5

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Andrea Giaccari, Anna Solini, Simona Frontoni, Stefano Del Prato. Diabetes Care 2021
2


Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci,[...]. Front Med (Lausanne) 2021
0

Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus.
Masaki Nakagaito, Teruhiko Imamura, Shuji Joho, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa. Int Heart J 2021
0

Management of type 2 diabetes in chronic kidney disease.
Jefferson L Triozzi, L Parker Gregg, Salim S Virani, Sankar D Navaneethan. BMJ Open Diabetes Res Care 2021
0

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
27

Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Ruth L Coleman, Alastair M Gray, Uli C Broedl Md, David Fitchett, Jyothis T George, Hans J Woerle, Bernard Zinman, Rury R Holman. Diabetes Obes Metab 2020
6


Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
1